LoginRegister

    Glenmark Pharma gets USFDA nod for generic version of Nexium to treat acid reflux

    Farhat NasimWritten by Farhat Nasim   |  
    Glenmark Pharma gets USFDA nod for generic version of Nexium to treat acid reflux

    The approved products Esomeprazole Magnesium delayed-release capsule is a generic version of AstraZeneca Pharmaceuticals' Nexium delayed-release capsules.


    New Delhi: Glenmark Pharmaceuticals on May 14 said it has received final approval from the US health regulator for a generic version of AstraZeneca's Nexium, used to treat acid reflux.


    Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food & Drug Administration (US FDA) for Esomeprazole Magnesium delayed-release capsules USP in the strengths of 20 mg and 40 mg, the company said in a BSE filing.


    The approved products is a generic version of AstraZeneca Pharmaceuticals' Nexium delayed-release capsules.


    Also Read: Glenmark launches SGLT2 Inhibitor Remogliflozin under brand names Remo, Remozen




    Citing IQVIA sales data, Glenmark said, Nexium delayed-release capsules, 20 mg and 40 mg achieved annual sales of around $395.1 million in the 12-month period ended March 2019.


    The company said its current portfolio consists of 153 products authorised for distribution in the US and 58 ANDA's pending approval with the USFDA.



    acidacid reflux medicationacidity drugAstraZenecaAstraZeneca PharmaEsomeprazole MagnesiumEsomeprazole Magnesium delayed-release capsulesgastric drugGlenmarkGlenmark PharmaGlenmark PharmaceuticalsGlenmark Pharmaceuticals drugNexiumstomach ache drugUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X